Top Markets
Coin of the day
Gongwin Biopharm Holdings Co., Ltd. Gongwin Biopharm Holdings Co., Ltd.

Gongwin Biopharm Holdings Co., Ltd.

6617
Clasificación en acciones #13752
Gongwin Biopharm Holdings Co., Ltd. is a clinical-stage biopharmaceutical... Gongwin Biopharm Holdings Co., Ltd. is a clinical-stage biopharmaceutical company specializing in the development of oncology therapeutics. The company's robust pipeline features several drug candidates, including PTS302, which has successfully concluded Phase III clinical trials for lung cancer. Additionally, PTS100 is currently progressing through Phase II clinical trials for liver cancer, while PTS-02 is being developed to address adenoid cystic carcinoma, and PTS500 targets malignant pleural effusion. Established in 2014, Gongwin Biopharm is headquartered in Taipei, Taiwan.
Precio por acción
$3.83
Capitalización bursátil
$464.45M
Cambio (1 día)
-1.63%
Cambio (1 año)
17.17%
País
TW
Comercio Gongwin Biopharm Holdings Co., Ltd. (6617)

Categoría

Ratio P/B de Gongwin Biopharm Holdings Co., Ltd. (6617)
Ratio P/B al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de Gongwin Biopharm Holdings Co., Ltd., el ratio P/B actual (TTM) es 0. Al final de 2026, el ratio P/B era 0.
Historial del ratio P/B de Gongwin Biopharm Holdings Co., Ltd. desde 2026 hasta 2026
Ratio P/B al final de cada año
Año Ratio P/B Cambiar
Not enough data for the provided dates.
Ratio P/B de empresas similares o competidoras
Empresa Ratio P/B Diferencia del ratio P/B País
-24.3279 -
US
- -
US
-19.2508 -
US
- -
US
5.5898 -
AU